Geftinat

Geftinat® is a specialized oncology medication containing 250 mg of Gefitinib, manufactured under strict quality standards by NATCO. As a selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, it targets the specific molecular pathways responsible for cancer cell proliferation. It is primarily indicated for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors express EGFR exon 19 deletions or exon 21 substitution mutations. Each pack contains 30 tablets engineered to deliver precise, targeted therapy, offering healthcare professionals a reliable tool to block signaling cascades that promote tumor growth.